RSC Med. Chem., 2023, 14,1002-1011
DOI: 10.1039/D2MD00441K, Opinion Open Access   This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Suzanne Ackloo, Albert A. Antolin, Jose Manuel Bartolome, Hartmut Beck, Alex Bullock, Ulrich A. K. Betz, Jark Böttcher, Peter J. Brown, Menorca Chaturvedi, Alisa Crisp, Danette Daniels, Jan Dreher, Kristina Edfeldt, Aled M. Edwards, Ursula Egner, Jon Elkins, Christian Fischer, Tine Glendorf, Steven Goldberg, Ingo V. Hartung, Alexander Hillisch, Evert Homan, Stefan Knapp, Markus Köster, Oliver Krämer, Josep Llaveria, Uta Lessel, Sven Lindemann, Lars Linderoth, Hisanori Matsui, Maurice Michel, Florian Montel, Anke Mueller-Fahrnow, Susanne Müller, Dafydd R. Owen, Kumar Singh Saikatendu, Vijayaratnam Santhakumar, Wendy Sanderson, Cora Scholten, Matthieu Schapira, Sujata Sharma, Brock Shireman, Michael Sundström, Matthew H. Todd, Claudia Tredup, Jennifer Venable, Timothy M. Willson, Cheryl H. Arrowsmith
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological
Target 2035 – an update on private sector contributions
